Visium Asset Management’s Pacira BioSciences PCRX Stock Holding History

Visium Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-2,239,098	Closed	-$119M	–	451
2016 Q1	$119M	Sell	2,239,098 -51,912	-2%	-$3.04M	2.02%	4
2015 Q4	$176M	Sell	2,291,010 -660,374	-22%	-$37.4M	2.64%	4
2015 Q3	$121M	Buy	2,951,384 +2,336,584	+380%	+$143M	1.66%	7
2015 Q2	$43.5M	Buy	+614,800	New	+$48.4M	0.62%	31
2015 Q1	–	Sell	-150,072	Closed	-$13.3M	–	1155
2014 Q4	$13.3M	Buy	+150,072	New	+$14.2M	0.19%	97
2014 Q3	–	Sell	-438,318	Closed	-$40.3M	–	1174
2014 Q2	$40.3M	Sell	438,318 -591,682	-57%	-$45.1M	0.63%	23
2014 Q1	$72.1M	Sell	1,030,000 -110,000	-10%	-$7.48M	1.17%	12
2013 Q4	$65.5M	Buy	1,140,000 +155,000	+16%	+$8.15M	1.29%	11
2013 Q3	$47.4M	Sell	985,000 -1,025,000	-51%	-$37.4M	1.07%	17
2013 Q2	$58.3M	Buy	+2,010,000	New	+$58.1M	1.36%	14

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Visium Asset Management's PCRX Position: Q2 2016 in Review

Visium Asset Management sold out of Pacira BioSciences (PCRX) in Q2 2016, closing a stake of 2,239,098 shares — an estimated $119M sold.

Visium Asset Management first reported a position in PCRX in Q2 2013 and held it in 10 quarters. The position peaked at $176M in Q4 2015. 183 funds tracked by Wall St. Rank hold PCRX as of Q2 2016.

Visium Asset Management reported no remaining Pacira BioSciences position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 2,239,098 Pacira BioSciences shares in Q2 2016, an estimated $119M.
Visium Asset Management first reported a position in Pacira BioSciences in Q2 2013 and held it in 10 quarters.
Visium Asset Management's Pacira BioSciences position peaked at $176M in Q4 2015.
183 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.